Janssen Pharmaceutical Companies of Johnson & Johnson recently released its announcement of more than 80 company-sponsored and investigator-initiated abstracts and studies included in the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition. Their portfolio covers a range of possible new therapies for a variety of hematologic diseases, as well as examinations into the possible healthcare disparities for patients with multiple myeloma.
One of the medications highlighted by Janssen at ASH 2021 will be ibrutinib (IMBRUVICA®), a Bruton’s tyrosine kinase (BTK) protein blocker developed in collaboration with Pharmacyclics LLC, an AbbVie company. With over 11 years of data already thoroughly evaluating the safety and efficacy of the medication, new real-world data is reinforcing the efficacy of using IMBRUVICA routinely in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (Abstract 4112).
This particular study found interesting results with patients’ time to next treatment when IMBRUVICA was included in treatment regimens, as well as insight into the impact the medication has on patients at high risk for atrial fibrillation or atrial fibrillation-related stroke.
Also included in Janssen’s portfolio is a retrospective chart review of patients with multiple myeloma, looking specifically at the different outcomes, treatment patterns, and patient characteristics between races (Abstract 1965). Over 250 Black and white patients who initiated the use of daratumumab during treatment were compared for the study. Ultimately, the term found clear differences in treatment patterns between races and indicated the need to further examine the disparities for patients with multiple myeloma.
With these studies and many more being presented at ASH 2021, Janssen continues on the path to enriching the understanding of blood cancers .